1.This Act may be cited as the
Scleroderma Research and Awareness Act
of 2010
.
2.National
institute of arthritis and musculoskeletal and skin diseases; scleroderma
research expansionPart B of
title IV of the Public Health Service Act (42 U.S.C. 284 et seq.) is amended by
adding at the end the following:
409K.The Director of NIH
may expand, intensify, and coordinate the activities of the National Institutes
of Health with respect to scleroderma, with particular emphasis on the
following:
(1)Research focused
on the etiology of scleroderma and the development of new treatment options.
(2)Clinical research
to evaluate new treatments options.
(3)Basic research on
the relationship between scleroderma and secondary conditions such as pulmonary
hypertension, gastroparesis, Raynaud's phenomenon, Sjögren's Syndrome, and
other diseases as determined by the
Director.
.
3.Promoting public
awareness of sclerodermaPart
P of title III of the Public Health Service Act (42 U.S.C. 280g et seq.) is amended
by adding at the end the following:
399V–5.Promoting
public awareness of sclerodermaThe Secretary may carry out an educational
campaign to increase public awareness of scleroderma. Print, video, and
Web-based materials distributed through this campaign may include—
(1)basic information
on scleroderma and its symptoms; and
(2)information
on—
(A)the incidence and
prevalence of scleroderma;
(B)diseases and
conditions affiliated with scleroderma; or
(C)the importance of
early diagnosis and treatment of
scleroderma.
.
Passed the House of Representatives September 30
(legislative day September 29), 2010.
Lorraine C. Miller,
Clerk.